Cervical Cancer

Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.

Midway through the IMMUNOCERV trial, PDS0101 enhances the production of versatile CD8 killer T cells, leading to reduced tumor DNA and significant tumor shrinkage of over 60% in all patients with high-risk cervical cancer.

Discover the potential of tisotumab vedotin combinations and emerging treatment strategies in the evolving landscape of cervical cancer management.

Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.

Perspectives on the breakthrough antibody drug conjugate, tisotumab vedotin, its mechanism of action, and the significant clinical benefits it offers to patients with recurrent or metastatic cervical cancer, leading to FDA approval and promising results in a confirmatory trial.

In the first article of a 2-part series, Shannon N. Westin, MD, MPH, looks at the promising responses to tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

A supplemental biologics license application seeking the approval of pembrolizumab, external beam radiotherapy, and concurrent chemotherapy, followed by brachytherapy has been accepted for priority review by the FDA for advanced cervical cancer.

Further data support the recent accelerated FDA approval of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

An expert gynecologic oncologist reviews the biology of cervical cancer and discusses how HPV vaccination is increasingly playing a role in prevention.

Ritu Salani, MD, presents the case of a patient with cervical cancer and describes the typical disease presentation and risk factors.

According to Bradley J. Monk, MD, FACS, FACOG, et al, multiple studies have shown the potential of tisotumab vedotin in patients with recurrent or metastatic cervical cancer. More evidence is needed before the oncology community can fully adopt its use.

Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.

The Data Monitoring Committee for the phase 3 KEYNOTE-A18 clinical trial has announced that the study met one of its primary end points.

Bradley J. Monk, MD, FACS, FACOG, discusses findings from the phase 3 KEYNOTE-826 trial of the addition of pembrolizumab to chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.

According to phase 2 study results, the combination of prolgolimab, bevacizumab and platinum doublet chemotherapy showed promising efficacy and an adequate safety profile in cervical cancer.

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.

For cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.

With 30 months additional follow-up on the EMPOWER-Cervical 1 trial, cemiplimab monotherapy showed efficacy in patients with metastatic cervical cancer.

Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.